<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03321136</url>
  </required_header>
  <id_info>
    <org_study_id>BASEC-2017-01348</org_study_id>
    <nct_id>NCT03321136</nct_id>
  </id_info>
  <brief_title>Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)</brief_title>
  <acronym>LDR</acronym>
  <official_title>Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matthias Liechti</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Serotonin receptors, especially the 5HT2A receptor, are thought to be involved in the effects
      of various recreationally used psychedelic substances such as LSD. LSD potently stimulates
      the 5-HT2A receptor but also 5-HT2B/C, 5-HT1 and dopaminergic receptors. LSD induces acute
      transient alterations in waking consciousness including visual perceptual alterations,
      audio-visual synesthesia, derealization and depersonalization. LSD has therefore been used as
      experimental tool (&quot;psychotomimetic&quot;) in modern psychiatric research to study psychotic-like
      states and model psychosis in healthy subjects [1-5]. However, the dose-effects of 5-HT2A
      receptor stimulation by LSD has not yet been studied. Additionally, there is still very
      limited data to what extent the 5HT2A receptor contributes to LSD's effects and its role in
      the mediation of the full response to LSD at a high dose is unclear. A recent experimental
      human study showed the 5-HT2A receptor antagonist ketanserin fully blocked the subjective
      effects of a moderate dose of 100 µg of LSD [6]. But, whether the effects of a high 200 µg
      oral dose of LSD can be blocked by the selective pharmacological 5-HT2A antagonist ketanserin
      remains to be tested to confirm the critical role of the 5-HT2A receptor in more pronounced
      alterations of consciousness and perception. The present study therefore explores the role
      the 5-HT2A receptor in LSD-induced altered states of consciousness using escalating doses of
      LSD and the 5-HT2A receptor blocker ketanserin administered before a high dose of LSD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Altered states of consciousness</measure>
    <time_frame>18 months</time_frame>
    <description>total 5D-ASC score (5-Dimensional Altered States of Consciousness Rating Scale)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective effects</measure>
    <time_frame>18 months</time_frame>
    <description>VAS (Visual analog scales)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective effects</measure>
    <time_frame>18 months</time_frame>
    <description>AMRS scales (Adjective mood rating scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychotomimetic effects</measure>
    <time_frame>18 months</time_frame>
    <description>ESI scale (Eppendorf Schizophrenia Inventory)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mystical-type experiences</measure>
    <time_frame>18 months</time_frame>
    <description>MS scales (Mysticism scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mystical-type experiences</measure>
    <time_frame>18 months</time_frame>
    <description>SCQ scales (States of consciousness questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic effects</measure>
    <time_frame>18 months</time_frame>
    <description>Blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic effects</measure>
    <time_frame>18 months</time_frame>
    <description>Heart Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic effects</measure>
    <time_frame>18 months</time_frame>
    <description>Body temperature</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo, LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100, LSD-200</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LSD</intervention_name>
    <description>0.025 mg LSD per os, single dose</description>
    <arm_group_label>Placebo, LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin</arm_group_label>
    <arm_group_label>LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo</arm_group_label>
    <arm_group_label>LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25</arm_group_label>
    <arm_group_label>LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50</arm_group_label>
    <arm_group_label>LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100</arm_group_label>
    <arm_group_label>LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100, LSD-200</arm_group_label>
    <other_name>Lysergic Acid Diethylamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LSD</intervention_name>
    <description>0.05 mg LSD per os, single dose</description>
    <arm_group_label>Placebo, LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin</arm_group_label>
    <arm_group_label>LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo</arm_group_label>
    <arm_group_label>LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25</arm_group_label>
    <arm_group_label>LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50</arm_group_label>
    <arm_group_label>LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100</arm_group_label>
    <arm_group_label>LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100, LSD-200</arm_group_label>
    <other_name>Lysergic Acid Diethylamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LSD</intervention_name>
    <description>0.1 mg LSD per os, single dose</description>
    <arm_group_label>Placebo, LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin</arm_group_label>
    <arm_group_label>LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo</arm_group_label>
    <arm_group_label>LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25</arm_group_label>
    <arm_group_label>LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50</arm_group_label>
    <arm_group_label>LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100</arm_group_label>
    <arm_group_label>LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100, LSD-200</arm_group_label>
    <other_name>Lysergic Acid Diethylamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LSD</intervention_name>
    <description>0.2 mg LSD per os, single dose</description>
    <arm_group_label>Placebo, LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin</arm_group_label>
    <arm_group_label>LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo</arm_group_label>
    <arm_group_label>LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25</arm_group_label>
    <arm_group_label>LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50</arm_group_label>
    <arm_group_label>LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100</arm_group_label>
    <arm_group_label>LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100, LSD-200</arm_group_label>
    <other_name>Lysergic Acid Diethylamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LSD</intervention_name>
    <description>0.2 mg LSD plus 40 mg ketanserin per os, single doses each</description>
    <arm_group_label>Placebo, LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin</arm_group_label>
    <arm_group_label>LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo</arm_group_label>
    <arm_group_label>LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25</arm_group_label>
    <arm_group_label>LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50</arm_group_label>
    <arm_group_label>LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100</arm_group_label>
    <arm_group_label>LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100, LSD-200</arm_group_label>
    <other_name>Lysergic Acid Diethylamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules containing mannitol looking identical to the other drugs.</description>
    <arm_group_label>Placebo, LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin</arm_group_label>
    <arm_group_label>LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo</arm_group_label>
    <arm_group_label>LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25</arm_group_label>
    <arm_group_label>LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50</arm_group_label>
    <arm_group_label>LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100</arm_group_label>
    <arm_group_label>LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100, LSD-200</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 25 and 65 years.

          2. Understanding of the German language.

          3. Understanding the procedures and the risks associated with the study.

          4. Participants must be willing to adhere to the protocol and sign the consent form.

          5. Participants must be willing to refrain from taking illicit psychoactive substances
             during the study.

          6. Participants must be willing to drink only alcohol-free liquids and no coffee, black
             or green tea, or energy drink after midnight of the evening before the study session,
             as well as during the study day.

          7. Participants must be willing not to drive a traffic vehicle or to operate machines
             within 48 h after substance administration.

          8. Women of childbearing potential must have a negative pregnancy test at the beginning
             of the study. Pregnancy tests are repeated before each study session.

          9. Women of childbearing potential must be willing to use double-barrier birth control

         10. Body mass index 18-29 kg/m2.

        Exclusion Criteria:

          1. Chronic or acute medical condition

          2. Current or previous major psychiatric disorder

          3. Psychotic disorder in first-degree relatives

          4. Illicit substance use (with the exception of cannabis) more than 10 times or any time
             within the previous two months.

          5. Pregnant or nursing women.

          6. Participation in another clinical trial (currently or within the last 30 days)

          7. Use of medications that may interfere with the effects of the study medications (any
             psychiatric medications)

          8. Tobacco smoking (&gt;10 cigarettes/day)

          9. Consumption of alcoholic drinks (&gt;10/week)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matthias E Liechti, MD, MAS</last_name>
    <phone>61 328 68 68</phone>
    <phone_ext>+41</phone_ext>
    <email>matthias.liechti@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Friederike Holze, MSc</last_name>
    <phone>61 328 68 61</phone>
    <phone_ext>+41</phone_ext>
    <email>friederike.holze@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias E Liechti, Prof. Dr. med.</last_name>
      <email>matthias.liechti@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Friederike Holze, MSc</last_name>
      <email>friederike.holze@usb.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2017</study_first_submitted>
  <study_first_submitted_qc>October 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2017</study_first_posted>
  <last_update_submitted>November 28, 2017</last_update_submitted>
  <last_update_submitted_qc>November 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Basel, Switzerland</investigator_affiliation>
    <investigator_full_name>Matthias Liechti</investigator_full_name>
    <investigator_title>Prinicipal Investigator (Prof. Dr. med.)</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Serotonin</mesh_term>
    <mesh_term>Lysergic Acid Diethylamide</mesh_term>
    <mesh_term>Ketanserin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

